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lzheimer’s disease (AD) is the most common
form of dementia. Although there are rare cases with
familial (autosomal dominant) forms of AD,the major-
ity of patients have the sporadic form of the disease.
1
Neuropathologically,AD is characterized by degenera-
tion of neurons and their synapses,and the presence of
extensive amounts of senile plaques and neurofibrillary
tangles.
2
Due to the increase in longevity,the prevalence of AD
will rise dramatically within the next few decades so that
an estimated 20 to 30 million people in the USA will be
living with AD by the year 2030.
3 The degenerative
process probably starts 20 to 30 years before the clinical
onset of AD.
4After the preclinical phase of the disease,
the first symptoms generally affect episodic memory.This
first clinical phase of AD without overt dementia is
referred to as the mild cognitive impairment (MCI)
phase of AD.
5
A diagnosis of MCI is based on memory disturbances
measures adjusted for age and education.
6 However,MCI
is an etiologically heterogeneous disorder.Although many
patients with MCI have incipient AD,others have a benign
form of MCI as part of the normal aging process.The con-
version rate of MCI to AD with dementia has been
reported to be as high as 15% per year.
5 Moreover,other
types of pathology,such as cerebrovascular disease,may
contribute to the memory impairment in MCI cases.Even
if cerebrovascular comorbidity can be suspected by means
of medical history (eg, presence of risk factors such as
hypertension),clinical examination (eg,focal neurological
symptoms), or brain imaging (eg, findings of infarcts or
white-matter lesions on computed tomography [CT] or
magnetic resonance tomography [MRT]),it may be diffi-
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Early diagnosis of Alzheimer’s disease (AD) is relevant in
order to initiate symptomatic treatment with antidemen-
tia drugs. This will be of greater significance if the drugs
aimed at slowing down the degenerative process (sec-
ondary prevention) prove to affect AD pathology and are
clinically effective, such as  -secretase inhibitors. However,
there is currently no clinical assessment to differentiate the
patients with mild cognitive impairment (MCI) who will
progress to AD from those with a benign form of memory
impairment that is part of the normal aging process. Thus,
there is great clinical need for diagnostic and predictive
biomarkers, as well as biomarkers for classification pur-
poses, to identify incipient AD in MCI subjects. The most
promising cerebrospinal fluid (CSF) biomarker candidates
are total tau protein (T-tau), phosphorylated tau protein
(P-tau), and the 42–amino acid form of  -amyloid (A 42),
which may, if used in the right clinical context, prove to
have sufficient diagnostic accuracy and predictive power
to resolve this diagnostic challenge. 
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Therefore,research efforts have focused on methods to
identify incipient AD in MCI subjects.
In this review,we present the rationale for the develop-
ment of cerebrospinal fluid (CSF) biomarkers of AD and
we discuss the potential of CSF biomarkers for the diag-
nosis of MCI.
Criteria and evaluation of biomarkers
Criteria for a useful biomarker have been proposed by
an international consensus group on molecular and bio-
chemical markers of AD.
7According to these guidelines,
a biomarker for AD should detect a manifestation of the
fundamental neuropathology and be validated in neu-
ropathologically confirmed cases. Its sensitivity for
detecting AD should exceed 85% and its specificity in
differentiating between AD and other dementias should
be at least 75%.Ideally,a biomarker test should also be
reliable, reproducible, noninvasive, simple to perform,
and inexpensive. One aspect of the test of particular
interest to patients and clinicians is its ability to detect
the disease at the earliest possible stage.To date,this has
been the weakness of neuropsychological techniques in
patients in the earliest clinical and even in the presymp-
tomatic phase of AD.Theoretically,an ideal diagnostic
biomarker of AD might be expected to show limited cor-
relation with cognitive performance,as the test should be
abnormal in patients who have few or no signs of cogni-
tive deterioration.Conversely,an ideal prognostic bio-
marker might be expected to show a significant correla-
tion with cognitive performance (or future cognitive
performance),as the test should be excessively abnormal
in patients who have a rapidly deteriorating course.Thus,
it is possible that different types of biomarkers will be
useful in different clinical situations.
A number of steps are required before a biomarker
becomes an asset to clinicians who treat patients with
AD.First,the technical feasibility of the new marker has
to be established,including the availability of a validated
assay with high precision and reliability of measurement
and well-described reagents and standards.A large range
of potential markers have successfully passed this first
step.Second,the possible marker has to be evaluated in
a relatively pure sample of diseased and comparison
groups.This is akin to the phase 2 trial in therapeutics,
but the goal here is to make an initial assessment of its
maximum sensitivity and specificity.Few potential mark-
ers have passed this step so far.Next,the new marker has
to be studied in a more representative population-based
sample, providing an assessment of its true diagnostic
properties and hence demonstrating its clinical useful-
ness.This step also serves as a basis for cost-effectiveness
analyses,which are important because every new marker
has to be evaluated in the context of the already avail-
able set of diagnostic and therapeutic options and the
socioeconomic resources of the health system.At pre-
sent, there are several multicenter initiatives with the
scope to evaluate new biomarkers in a population-based
design;one important example is the Working Group on
Biological Measures as part of the National Institute on
Aging (NIA) Alzheimer’s Neuroimaging Initiative.
8
Diagnostic biomarkers for AD and MCI
The availability of effective symptomatic treatment of
AD with cholinesterase inhibitors has highlighted the
importance of early and accurate diagnosis of AD among
clinicians.The awareness in the population of the possi-
bilities for drug treatment has also made patients seek
medical advice very early in the course of the disease.
In the MCI phase,the characteristic clinical picture of AD
has not yet developed,and there is no clinical method to
determine which MCI subjects will progress to AD except
with follow-up visits.Thus,there is a great need for diag-
nostic instruments to identify incipient AD in MCI cases.
This need will grow as new disease-modifying drugs
become available,such as β- and γ-secretase inhibitors or
β-amyloid (Aβ) vaccination.Such compounds will proba-
bly be most effective in the earlier stages of the disease
before neurodegeneration is too severe and widespread.
Basic research
380
Selected abbreviations and acronyms
AD Alzheimer’s disease
APP amyloid precursor protein
A   -amyloid
CJD Creutzfeldt-Jakob disease
FTD frontotemporal dementia
HC healthy control
LBD  Lewy body dementia
MCI mild cognitive impairment
PD Parkinson’s disease
PHF paired helical filament
P-tau phosphorylated tau protein
T-tau total tau protein
VD vascular dementiaThe neurochemistry of AD
Aβ and senile plaques
A major breakthrough in AD research was the identifi-
cation of Aβ as the main protein constituent of plaques.
9
Aβ is generated by proteolytic cleavage of its precursor,
the amyloid precursor protein (APP).
10APP is a single
membrane–spanning protein with a large ectodomain
and a smaller cytoplasmic tail,
11 a schematic drawing of
APP is given in Figure 1.
In the first step,Aβ is produced by cleavage of APP after
position 671 by a protease referred to as β-secretase
(Figure 1),which has been identified as β-site APP-cleav-
ing enzyme (BACE).
12This cleavage results in the release
of a large N-terminal derivative called β-secretase–cleaved
soluble APP (βsAPP) (Figure 1).In the second step,the
99–amino acid C-terminal fragment (CTF) of APP (C99)
is cleaved by the γ-secretase-complex–releasing free Aβ
(Figure 1).Recent studies have shown that the presenilins
constitute the catalytic subunit of the γ-secretase.
13 The
membrane proteins nicastrin,APH1a,APH1b,and PEN2
regulate the γ-secretase cleavage,
14-16 and together with pre-
senilin form a functional complex,the γ-secretase complex,
responsible for cleavage of the APP CTF.
Another breakthrough was the discovery that there are
several C-terminal forms of Aβ,and that the longer form
ending at Ala-42 (Aβ42) was found to aggregate more
rapidly than the shorter Aβ40 form,and to be the initial
and predominant Aβ form deposited in plaques.
17-20
Tau and neurofibrillary tangles
Tau protein is a microtubule-associated protein located in
the neuronal axons. Due to alternative splicing of tau
mRNA,there are 6 isoforms ranging in size from 352 to 441
amino acids,with molecular weights ranging from 50 to 65
kDa (Figure 2).
21-24Tau binds to tubulin in the axonal micro-
tubules,thereby promoting microtubule assembly and sta-
bility.
21Tau protein has more than 30 phosphorylation sites,
21
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Figure 1. Schematic drawing of the generation of β-amyloid (Aβ) from its precursor, amyloid precursor protein (APP). APP is a transmembrane protein
with a large extracellular N-terminal domain and a smaller intracellular tail. The Aβ domain is partly embedded in the plasma membrane. In
the amyloidogenic pathway, APP is first cleaved by β-secretase, resulting in the release of β-secretase–cleaved soluble APP (β-sAPP). In the sec-
ond step, the 99–amino acid C-terminal fragment (CTF, C99) of APP is cleaved by the γ-secretase-complex–releasing free Aβ. KPI, Kunitz pro-
tease inhibitor; OX2, OX2 antigen.
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APP 770either threonine or serine (Figure 2b). In AD, an abnor-
mally hyperphosphorylated form of tau is the principal
component of the paired helical filaments (PHFs),which
make up the neurofibrillary tangles,neuropil threads,and
senile plaque neuritis.
25 Due to the hyperphosphorylation,
tau loses its ability to bind to the microtubules and to stim-
ulate their assembly,and also gets a tendency to aggregate.
26
Aβ and tau in CSF as biomarkers for AD
The biochemical changes in the brain are reflected in
CSF,and so CSF is an obvious source in the search for
biomarkers for AD.There are two methods to search for
CSF biomarkers:the candidate biomarker approach and
the proteomic approach.
•The candidate biomarker approach is based on the neu-
rochemistry of the central pathogenic processes in AD.
Candidate biomarkers relate to proteins reflecting the
neuronal degeneration,the metabolism and aggrega-
tion of Aβ,as well as the hyperphosphorylation of tau
protein.
•The proteomic approach is based on the identification
of biomarkers that can differentiate AD from controls
and other brain disorders,regardless of whether they
are directly linked to the primary steps in AD patho-
genesis.Proteomic methods include two-dimensional
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Figure 2. A. Schematic drawing of the six isoforms of tau protein. Alternatively spliced exons are marked. At the top, the smallest tau isoforms con-
taining 352 amino acids, with three repeat (microtubule-binding) domains. Below the other two three-repeat tau isoforms with exon 2 and
exons 2 and 3 spliced in. The lower three tau isoforms contain four repeat domains. B. Schematic drawing of the largest tau isoform (tau 441),
with phosphorylation sites, either threonine (T) or serine (S), marked. Phosphorylated epitopes used in the ELISA (enzyme-linked immunosor-
bent assay) methods for quantification of phosphorylated tau (P-tau) in cerebrospinal fluid (CSF) are marked, including threonine 181,
22 ser-
ine 199,
23 and threonine 231.
24
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Belectrophoresis,protein chips,or liquid chromatogra-
phy combined with mass spectrometry.
27
Using the candidate biomarker approach,the three CSF
biomarkers,total tau protein (T-tau),Aβ42,and various
phosphorylated tau protein (P-tau) epitopes have been
examined in numerous studies, and have been found to
have high diagnostic potential.
Aβ42 isoform
The first studies on CSF total Aβ used ELISA (enzyme-
linked immunosorbent assay) methods that did not dis-
criminate between different Aβ isoforms. Although
some studies found a slight decrease in total CSF Aβ in
AD,
28-30 other studies found no change.
31-33
These negative results provided the conceptual basis for
the development of ELISA methods specific for
Aβ42.
31,34 A large number of studies have evaluated the
diagnostic potential for the most commonly used
method for Aβ42,
34,35 finding a sensitivity >85% and a
specificity of 90% for discriminating between AD and
normal aging.
36
The CSF level of Aβ42 is decreased in AD to about 40%
to 50% of control levels.
36 The reason for this decrease
is not clear.One explanation is that Aβ42 is deposited in
plaques,with lower amounts of Aβ being free to diffuse
into CSF.
32 This explanation is supported by the finding
of a strong correlation between low Aβ42 in ventricular
CSF and higher numbers of plaques in the neocortex
and hippocampus.
37 Subsequent studies also found,how-
ever,a marked reduction in CSF Aβ42 in disorders with-
out  βA plaques, such as Creutzfeldt-Jakob disease
(CJD),
38 amyotrophic lateral sclerosis,
39 and multiple sys-
tem atrophy.
40 These findings question the notion of a
direct reflection of senile plaque formation by Aβ1-42.
CSF Aβ1-42 in the differential diagnosis of AD and
other neurodegenerative disorders
The potential of CSF Aβ1-42 to distinguish AD from
other dementias and neurological disorders has been
documented in a number of independent studies.
Compared with nonAD dementias,a slight decrease has
been found in AD.
41 Normal levels
32 or decreased levels
42
were found in Parkinson’s disease (PD). In Lewy body
dementia (LBD), a disorder also characterized by the
presence of senile plaques, low levels have also been
detected,similar to AD.
43-46 In addition,low CSF Aβ1-42
is found in a relatively large percentage of patients with
frontotemporal dementia (FTD) and vascular dementia
(VD).
47,48 In summary,CSF Aβ1-42 does not seem to sig-
nificantly support the differential diagnosis of AD.
Predictive value of CSF Aβ1-42 in MCI for AD
It has been hypothesized that a decrease in CSF Aβ1-42
might indicate an early stage of AD and be detectable
before clinical symptoms of dementia become overt.
One study found a significant decrease in CSF Aβ1-42
in MCI subjects compared with controls.
43 In another
study in MCI patients who eventually developed AD,
however,Aβ1-42 levels did not differ significantly from
age-matched normal controls.
49 We found Aβ1-42 to be
an indicator of early identification of AD in MCI sub-
jects taking potential confounding factors into account,
such as age,severity of cognitive decline,time of obser-
vation, apolipoprotein E ε4 (APOE ε4) carrier status,
and gender.
50
Other Aβ isoforms
In contrast to the reduction in CSF Aβ42, there is no
change in CSF Aβ40 in AD, resulting in a marked
decrease in the ratio of CSF Aβ42/Aβ40.
51-55The reduc-
tion in the CSF Aβ42/Aβ40 ratio may be more pro-
nounced than the reduction in CSF Aβ42.
52-54 Further
studies will show whether the CSF Aβ42/Aβ40 ratio has
a larger diagnostic potential than CSF Aβ42 alone.
Studies using mass spectrometry,
56 urea-based SDS-
PAGE (sodium dodecylsulfate polyacrylamide gel elec-
trophoresis), Western immunoblot,
57 and surface-
enhanced laser desorption/ionization time-of-flight mass
spectrometry (SELDI-TOF)
58 have found that there is a
heterogeneous set of Aβ peptides in CSF. Preliminary
data show that increased CSF levels of both Aβ1-40 and
Aβ1-38 together with a decrease in Aβ1-42 are found in
AD.
57 Further studies are needed to examine the diag-
nostic potential of these Aβ species.
Total tau protein
After the first report on T-tau in CSF using an ELISA
method with a polyclonal reporter antibody,
59 an ELISA
method based on monoclonal antibodies detecting all
isoforms of tau independent of phosphorylation state of
tau was developed.
60,61 A large number of studies have
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monly used method for T-tau,
60 finding a sensitivity
above 80% and a specificity of 90% discriminate between
AD and normal aging.
36
T-tau in the differentiation between AD and normal
aging
T-tau has been intensely studied in more than 2000 AD
patients and 1000 age-matched elderly controls over the
last 5 to 10 years.
23,32,41,43,44,47,52,53,59-82The most consistent find-
ing is a statistically significant increase in CSF T-tau in
AD.The mean level of CSF T-tau concentration in AD
compared with elderly controls approaches 300%.
Across the reviewed studies, sensitivity and specificity
levels varied with the differently employed control
groups, statistical methods, and reference values.
Specificity levels were determined between 65% and
86% and sensitivity between 40% and 86%.
83 In several
studies,a significant elevation was even found in patients
with early dementia.
63,70,81 Therefore, in mild dementia,
the potential of CSF T-tau to discriminate between AD
and normal aging is high,with a mean sensitivity of 75%
and specificity of 85%.
An age-associated increase in T-tau has been shown in
nondemented subjects.
73,84 Therefore, the effect of age
should be considered when T-tau levels are diagnosti-
cally employed.Age-dependent reference values for nor-
mal T-tau have already been established:ages between
21 and 50 years at <300 pg/mL; ages between 51 to 70
years at <450 pg/mL;and ages between 70 and 93 years
at <500 pg/mL.
85
T-tau in the differentiation between AD and MD
Geriatric major depression (MD) is an important psy-
chiatric differential diagnosis of AD,as psychopatholog-
ical symptoms considerably overlap and often only a fol-
low-up assessment allows clear clinical differentiation
between both underlying entities.Subgrouping a sample
of AD patients,healthy controls (HCs),and patients with
MD according to age resulted in a correct classification
rate of 94.5% in the “young old”subjects (<70 years of
age) compared with only 68.4% in the “old old”(70 years
of age). This report supports the notion that elevated
CSF T-tau is highly indicative of a neurodegenerative
process particularly in subjects younger than 70 years of
age.
73
T-tau in the differential diagnosis of AD and other
neurodegenerative disorders
The potential of CSF T-tau,however,is limited in its abil-
ity to discriminate AD from other relevant dementia dis-
orders.At a sensitivity level of 81%,CSF T-tau reached
a specificity level of only 57% for distinguishing AD from
other dementias.
45,47
Due to these inconsistent findings caused by incomplete
or lacking control and comparison groups,and low speci-
ficity levels of T-tau in the differentiation of AD from
other primary dementias,the value of T-tau in the differ-
ential diagnosis was long inconclusive.Therefore,T-tau
has not been suggested as a marker for the differential
diagnosis of AD.T-tau rather reflects unspecific processes
of axonal damage and neuronal degeneration. This
notion is further supported by the increase in CSF T-tau
in disorders with extensive and/or rapid neuronal degen-
eration, such as CJD.
86,87 A highly significant increase 
of 580% was documented in CJD compared to AD
patients.At a cutoff level of 2130 pg/mL,T-tau yielded a
sensitivity of 93% and a specificity of 100% between AD
and CJD.
88An elevation of CSF T-tau,correlating with
clinical severity, has been shown in normal pressure
hydrocephalus.
89 Moreover,a marked transient increase
in CSF T-tau has been demonstrated after acute stroke.
The transient increase in CSF T-tau correlated with the
infarct size measured by cranial CT.
90 Elevated levels of
CSF T-tau have been found in patients with diffuse
axonal damage after traumatic brain injury, which
decrease with clinical improvement.
91 In contrast,in neu-
rological disorders that are mainly linked to more
restricted cerebral locations and number of cells,such as
alcoholic dementia,PD,progressive supranuclear palsy,
and corticobasal degeneration,elevated CSF T-tau con-
centrations have been only occasionally reported
48,60,68,76,92,93
or were normal.
77
Predictive value of CSF T-tau in MCI for AD
In patients suffering from MCI who converted to AD
during follow-up,elevated T-tau levels were found in rel-
atively few samples at baseline.
43,66 Memory-impaired
subjects who later progressed to manifest AD could be
discriminated by high CSF T-tau from those who did not
progress with 90% sensitivity and 100% specificity.
66
Longitudinally,elevated CSF levels of T-tau were found
in MCI subjects and remained elevated after conversion
Basic research
384to clinical AD.
49 Another study showed that 88% of
patients with MCI had elevated T-tau concentrations
and/or low CSF Aβ1-42 levels at baseline.
94Thus,elevated
CSF T-tau in MCI may have the potential to predict AD.
Phosphorylated tau protein
In order to improve specificity of measurement of tau
protein as a biomarker of AD,assays have been devel-
oped to specifically detect phosphorylated tau protein 
(P-tau) in CSF.These assays use monoclonal antibodies
specific for phosphorylated epitopes of tau:tau protein
phosphorylated at serine 199 (P-tau199), threonine 231
and serine 235 (P-tau231-235),
23 threonine 231 (P-tau231),
24
threonine 181 (P-tau181),
22,95 and serine 396 and serine 404
(P-tau396/404).
96
A marked increase in the CSF level of P-tau is found in
AD.
83This increase probably reflects the phosphorylation
state of tau,and thus possibly also the formation of tan-
gles in AD.Indirect evidence for this comes from studies
showing no change in CSF P-tau after acute stroke in
contrast to T-tau,
90 and normal CSF P-tau levels in CJD,
despite a very marked increase in T-tau.
97These studies
suggest that CSF P-tau is not simply a marker for neu-
ronal damage.
A clear increase in CSF P-tau in AD has been found
using all these ELISA methods,with a sensitivity of 80%
and a specificity above 90% to discriminate between AD
and normal aging.
36 Interestingly,a normal CSF level of
P-tau is not only found in psychiatric disorders such as
depression
98 and chronic neurological disorders such as
PD, but also in other dementia disorders, such as VD,
FTD, and LBD.
36 Thus, the specificity of CSF P-tau for
differentiating AD from other dementias seems to be
higher than for T-tau and Aβ42.
P-tau in the differential diagnosis of AD
CSF tau protein phosphorylated at threonine 231 
(P-tau231)
Immunohistochemical studies indicate that phosphoryla-
tion of tau protein at threonine 231 (P-tau231) appears
early in pathogenesis,even before PHF formation.
99The
first study of P-tau231 in CSF showed a discrimination
between AD patients and nondemented controls with
other neurological disorders with 85% sensitivity and 97%
specificity (overall accuracy of 91%).
24 In an independent
sample of 192 subjects,CSF levels of P-tau231 discriminated
with a sensitivity of 90.2% and a specificity of 80%
between AD and all other nonAD subjects.In particular,
at a specificity level of 92.3% for P-tau231 and T-tau,sensi-
tivity levels between AD and FTD were raised using 
P-tau231,in comparison to T-tau,from 57.7% to 90.2%.
100
In summary,P-tau231 may be a valuable biomarker,espe-
cially in the differential diagnosis between AD and FTD.
CSF tau protein phosphorylated at threonine 181 
(P-tau181)
The discriminative power of CSF P-tau181 has been inves-
tigated in a number of studies with various types of demen-
tia.Results showed a significant increase in CSF P-tau181
concentrations in AD compared with FTD and controls.
22
Focusing on the differentiation between AD and LBD,
specificity at a given sensitivity level was improved by using
P-tau181 compared with T-tau.
45,95 Comparing receiver oper-
ator characteristic (ROC) curves led to a correct classifi-
cation for cases with AD and LBD of more than 80%.
In a study with 101 subjects comparing P-tau181 and T-tau
in various diagnostic subgroups,P-tau181 was increased
in patients with probable and possible AD compared
with VD and dementia in PD.
84 Compared with FTD,PD,
VD,and normal aging,both P-tau181 and T-tau proteins
were increased in probable AD.In possible AD,P-tau181
was increased compared with FTD and VD. Recently,
data on a group of 51 AD patients (25 probable,18 pos-
sible,and 8 incipient AD cases) compared with 16 prob-
able VD cases and 10 HCs became available.
101All AD
cases were drug-naive.AD and VD,as well as HCs,were
distinguished using P-tau181,whereas VD compared to
HCs showed no statistically significant differences in con-
centration.Among the whole group of AD patients and
controls,P-tau181 demonstrated 71% sensitivity and 94%
specificity compared with T-tau with 63% sensitivity and
100% specificity.Taken together,diagnostic accuracy was
better for P-tau181 (78%) than for T-tau (71%).In sum-
mary,P-tau181 may be a valuable biomarker,especially in
the differential diagnosis between AD,LBD,and VD.
CSF tau protein phosphorylated at serine 199 
(P-tau199)
In one study applying P-tau199,this biomarker was shown
to be superior to T-tau protein in separating AD from a
patient group of nonAD subjects.
23 In a large multicen-
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102 P-tau199 protein levels were
elevated in the AD group,independently of age,gender,
cognitive status,and APOE ε4 carrier status.In the AD
group versus the combined groups of demented and non-
demented subjects in this study,ROC analysis showed a
85% sensitivity and 85% specificity for P-tau199.
102
CSF tau protein phosphorylated at serine 396 and 
serine 404 (P-tau396/404)
An ultrasensitive bienzyme-substrate-recycle ELISA for
Ser 396 and Ser 404 has been developed,which is signif-
icantly more sensitive than conventional ELISA in deter-
mining the hyperphosphorylated tau protein and T-tau.
96
In CSF of 52 AD patients, 56 normal controls, 46 VD
patients, and 37 nonAD neurological patients, signifi-
cantly elevated levels of P-tau396/404 were only found in
AD.Using the ratio of hyperphosphorylated tau protein
to T-tau of ≥0.33 as a cutoff for AD diagnosis,the clinical
diagnosis could be confirmed in 96% of the clinically
diagnosed patients.The results of this study suggest that
P-tau396/404 is a promising marker,especially in the dif-
ferential diagnosis between AD and VD.
Measurement of P-tau epitopes in the differential 
diagnosis of AD:a comparative CSF study
A recent study directly compared the diagnostic perfor-
mance of P-tau231, P-tau181, and P-tau199 in the same
patient cohort,including a large series of patients with AD,
LBD, FTD, VD, and other neurological disorders. The 
P-tau231 and P-tau181 assays performed nearly equally well
in the discrimination of AD from nondemented controls,
whereas the P-tau199 assay showed a weaker discrimina-
tion.
103 Interestingly,the separation between AD and FTD
was maximized using P-tau231.The separation between
AD and DLB was maximized using P-tau181.
103Thus,dif-
ferences in the phosphorylation of specific tau epitopes
between dementia disorders may be reflected in the CSF
level of the corresponding P-tau variant.
Predictive value of CSF P-tau in MCI for AD
In a longitudinal study,77 MCI patients showed elevated
levels for P-tau231 in comparison to HCs at baseline.
104
High CSF P-tau231,but not T-tau levels at baseline,sig-
nificantly correlated with subsequent cognitive decline.
This study suggests that high P-tau231 may be a predictor
for progressive cognitive decline in subjects with MCI.
104
One study focused on P-tau231-235 in MCI subjects who
converted to AD compared to individuals with subjective
memory complaints without cognitive impairment.
Results showed significantly higher T-tau and P-tau231-235
levels in the MCI group.P-tau231-235 yielded a specificity
level of 100% and a sensitivity level of 65% for differen-
tiating MCI subjects who eventually developed AD.
105
In a recent study on 44 MCI subjects who later pro-
gressed to AD,P-tau181 was found to differentiate MCI
from controls with 70% sensitivity and 90% specificity.
106
Although further longitudinal studies are needed,these
data suggest that CSF markers are positive very early in
the disease process in AD,and may be of clinical value to
differentiate MCI subjects with incipient AD.
Conclusion
In conclusion,the immunoassays detecting P-tau protein,
T-tau protein,and Aβ proteins promise improvements in
the early and accurate diagnosis of incipient AD.Beyond
early diagnosis,it is hoped that markers of prognosis will
enable clinicians to monitor whether new candidate treat-
ments of AD are working effectively and inexpensively.
With this in mind, the NIA commissioned a working
group on biomarkers as part of its Alzheimer’s
Neuroimaging Initiative.
8 The Working Group on
Biological Measures suggested tau proteins as well as Aβ
proteins as feasible core markers suitable for a multicen-
ter,longitudinal study of AD,with special consideration
given to MCI.In addition,the NIA also established other
working groups,one each for magnetic resonance imag-
ing (MRI,volumetric),positron emission tomography and
single photon emission computed tomography (PET and
SPECT),and subjects and protocol design.The accuracy
of any diagnostic test in AD is likely to be increased by
the cumulative information from clinical and neuropsy-
chological examination,and brain imaging.
107,108 Further
work is required here, particularly in relation to CSF 
P-tau.The proceedings of such working groups in Europe
and the USA will greatly assist individual clinicians and
health service providers in deciding which specific diag-
nostic tests should be standard practice in the assessment
of incipient AD in MCI subjects. ❏
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Tau y beta amiloide en líquido céfalo-raquí-
deo como marcadores del deterioro cogni-
tivo leve
El diagnóstico precoz de la enfermedad de
Alzheimer (EA) es primordial para iniciar un trata-
miento sintomático con fármacos antidemencia.
Esto será de mayor significación si los fármacos
orientados a retrasar el proceso degenerativo (pre-
vención secundaria) demuestran que afectan la
patología de la EA y son clínicamente eficaces,
como los inhibidores de la  -secretasa. Sin
embargo, actualmente no hay evaluaciones clíni-
cas que permitan diferenciar los pacientes con
deterioro cognitivo leve (DCL) que evolucionarán
hacia una EA de aquéllos con una forma benigna
de deterioro de memoria que es parte del proceso
de envejecimiento normal. Por lo tanto, existe una
gran necesidad clínica de contar con biomarcado-
res diagnósticos y predictores, como también bio-
marcadores con fines de clasificación, para identi-
ficar una EA incipiente en sujetos con DCL. Los
biomarcadores candidatos del líquido céfalo-raquí-
deo más prometedores son la proteína tau total (T-
tau), la proteína tau fosforilada (P-tau) y la forma
del  -amiloide de 42 aminoácidos (A 42), los cua-
les pueden probar que tienen una suficiente pre-
cisión diagnóstica y un alto poder predictivo para
resolver este desafío diagnóstico si se utilizan en
un adecuado contexto clínico.
Protéines tau et  -amyloïde du liquide céré-
brospinal comme marqueurs biologiques du
déficit cognitif léger
Un diagnostic précoce de la maladie d’Alzheimer
(MA) est pertinent pour débuter un traitement
symptomatique avec des médicaments contre la
démence. Cette démarche sera d’autant plus inté-
ressante que ces médicaments destinés à ralentir le
processus dégénératif (prévention secondaire)
prouvent qu’ils agissent sur la MA et sont clinique-
ment efficaces, tels les inhibiteurs de la  -sécrétase.
Cependant, il n’y a actuellement aucune évaluation
clinique pour différencier les patients présentant un
déficit cognitif léger (Mild Cognitive Impairment,
MCI) qui développeront une MA de ceux présen-
tant une forme bénigne de troubles de la mémoire
en rapport avec le processus de vieillissement nor-
mal. Il existe donc un grand besoin clinique au
niveau des marqueurs biologiques diagnostiques et
prévisionnels, ainsi que des marqueurs biologiques
pour des besoins de classification et pour identifier
une MA débutante chez des sujets présentant un
MCI. Les candidats les plus prometteurs parmi les
marqueurs biologiques du liquide cérébrospinal
sont la protéine tau totale (T-tau), la protéine tau
phosphorylée (P-tau) et la forme de la protéine 
 -amyloïde comportant 42 acides aminés (A 42),
qui pourraient, utilisés dans un contexte clinique
adapté, montrer une exactitude diagnostique et un
pouvoir prévisionnel suffisants pour résoudre ce
défi.
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